ASBAP A.I CyberSecurity Scoring
19/03/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Advanced Surgery at Baxter Asia Pacific in 2026.
No incidents recorded for Advanced Surgery at Baxter Asia Pacific in 2026.
No incidents recorded for Advanced Surgery at Baxter Asia Pacific in 2026.
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. We partner with customers across the globe to help them solve their most complex challenges, architecting solutions that bring the power of science to life. Our global teams are pioneering what’s next across Life Sciences, Diagnostics, Biotechnology and beyond. For more information, visit www.danaher.com.
We are dedicated to transforming lives by improving the journey to a healthy, beautiful smile. Discover your straight path to a bright future at Align Technology. As a part of our smart, diverse and fast-moving global team, you'll make an impact on the market leader that's moving an industry forward. Want to find out what's next for us—and for you? Follow us on LinkedIn for business updates and check out our current opportunities at www.aligntech.com/careers. 25 years ago, we pioneered the market for clear aligners. Since then, we have continuously innovated with new products and technologies that revolutionize treatments for doctors and their patients. Today, doctors and labs in over 100 markets use the Invisalign system, iTero intraoral scanners and exocad software to improve smiles for patients – from simple tooth alignment to complex corrections, kids to adults, orthodontics to multi-disciplinary restorative treatment. Learn more about Align Technology and our products: www.aligntech.com www.invisalign.com www.itero.com www.exocad.com
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We advance our mission to alleviate pain and improve the quality of life for patients around the world with our innovative products and suite of integrated digital and robotic technologies leverage data, data analytics and artificial intelligence. Founded in 1927 and based in Warsaw, Zimmer Biomet has operations in more than 25 countries and sales in more than 100 countries. We maintain world-class scientific facilities and resources and collaborate with leading clinicians and researchers around the world. Awards and Recognitions • Forbes: America's Best Companies 2026 • Workhuman: Luminary Award 2025 & Innovator Award 2024 • TIME: America's Best Companies [Mid-Size] 2024 • Great Place to Work - Best Workplaces: Switzerland & Poland 2025 • Great Place to Work Certified 2025 - 2026: USA, Poland, India, Colombia, Ireland, Puerto Rico, Kingdom of Saudi Arabia, Switzerland • MedTech: Breakthrough Award Best New Technology Solution in Orthopedics 2025 • Top Employers Institute: China 2025 • VETS Indexes: 4 Star Employer 2025
Edwards Lifesciences (NYSE: EW), is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. We thrive on discovery and expanding the boundaries of medical technology, serving patients in 100+ countries, with the help of our employees in areas including Clinical Affairs, Quality Engineering, Research & Development, Regulatory Affairs, Sales & Marketing, corporate functions and more. Contact Us We want to hear from you and engage in meaningful discussions. However, please note that we are not equipped to provide customer, candidate, or technical support through this platform. If you require assistance from those teams, please find their contact information here: https://www.edwards.com/aboutus/contactus If you’re a patient in need of medical advice, please contact your healthcare provider directly. We reserve the right to remove any comments that are off-topic, repetitive, or include hate speech, profanity, or offensive language. Additionally, we will not engage in discussions about competitor products, off-label use of Edwards products, or unsubstantiated/misleading claims that could cause harm. All Terms and Conditions of LinkedIn apply. For the Edwards Lifesciences privacy policy, visit https://www.edwards.com/legal/privacypolicy.
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at stryker.com and careers.stryker.com. Facts: ● 2024 Sales: $22.6 billion ● Industry: Medical Instruments & Supplies ● Employees: 53,000 worldwide ● 40 years of sales growth leading up to 2020 ● 44+ Manufacturing and R&D Locations Worldwide ● $1.5 billion spent on research and development in 2024 ● ~14,200 patents owned globally in 2024 ● Products sold in ~75 countries ● Fortune 500 Company ● 7 consecutive years as one of Fortune's World's Best Workplaces Stryker’s social media community guidelines: https://www.stryker.com/content/m/legal/social-media-community-guidelines/en/index.html Notice Regarding Employee Conduct on Facebook/LinkedIn Meta/LinkedIn does not permit employers to verify or validate “employees” in the (META: “Works at” LinkedIn: “Experience”) section of users’ profiles. Please be aware that the views expressed by individuals on their personal accounts and do not necessarily represent the views of our company. If you encounter any issues with a person claiming to be our employee, we recommend using the “Report Profile” feature. If you’d like to report concerns to our Ethics Hotline, you may do so at: https://app.convercent.com/en-us/LandingPage/b6bb4e84-9fcb-ea11-a974-000d3ab9f296
STERIS is a leading provider of infection prevention and other procedural products and services, focused primarily on healthcare, pharmaceutical and medical device Customers. MISSION WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. VISION We strive to be a GREAT COMPANY. We provide world-class products and services for our Customers, safe and rewarding work for our people, and superior returns for our Shareholders. • $5 Billion in revenue in FY24 • More than 17,000 Associates worldwide • Over 4,000 Customer-facing professionals • Listed on the New York Stock Exchange under the symbol “STE” To learn more, visit www.steris.com. Want to join the team? View and apply for open roles at careers.steris.com.
Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its unique offering of world-class products, supply chain resilience and clinical practice expertise, Medline delivers improved clinical, financial and operational outcomes. Headquartered in Northfield, Illinois, the company employs 43,000 people worldwide and operates in over 100 countries and territories. To learn more about how Medline makes healthcare run better, visit www.medline.com.
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love to innovate and develop exciting technologies, and we offer competitive salaries and progressive benefits. But it’s our culture - of Care, Collaboration and Courage - that really sets us apart. Through a spirit of ownership and can-do attitude, we work together to win.. We’re a company of people who care about each other, about our customers and their patients, and about our communities. Together, we fulfill our shared purpose of Life Unlimited. Please note: not all products referred to may be approved for use or available in all markets.
Latest updates, reports, and threat intel affecting the global network.
While acute therapies saw over 40% growth during the quarter, sales in Baxter's advanced surgery, medication delivery and pharma businesses...
Craft CMS is a content management system (CMS). In versions 5.0.0-RC1 through 5.9.22 and 4.0.0-RC1 through 4.17.15, an attacker with only a GitHub account can plant a JavaScript payload in a craftcms/cms issue title. When a Craft admin uses the CraftSupport widget’s "Give feedback" screen and types a search term that returns the poisoned issue, the payload executes in the admin’s control panel session. No control panel account or elevated privileges are required on the attacker’s side. This issue has been fixed in versions 4.17.16 and 5.9.23.
Craft CMS is a content management system (CMS). In versions 5.0.0-RC1 through 5.9.21 and 4.0.0-RC1 through 4.17.14, theAssetsController::actionDeleteFolder() only requires the deleteAssets:<volume-uid> permission for the target folder. It never enforces deletePeerAssets:<volume-uid>, even though Assets::deleteFoldersByIds() cascades deletion to every descendant folder and every asset inside, regardless of the uploader's assigned privileges. A low-privilege user who has been granted folder-management rights on a shared volume can therefore destroy assets uploaded by other users (peer assets), bypassing the per-asset peer-permission check that the sibling actionDeleteAsset endpoint correctly applies. This issue has been fixed in versions 4.17.15 and 5.9.22.
Craft CMS is a content management system (CMS). Versions 5.0.0-RC1 through 5.9.20, and 4.0.0-RC1 through 4.17.13 contain an authorization issue in the AssetsController::actionReplaceFile that can delete a source asset without source delete permission by supplying both assetId and sourceAssetId. AssetsController::actionReplaceFile() supports replacing a target asset file using another existing asset as the source. The action loads: assetId -> $assetToReplace and sourceAssetId -> $sourceAsset, then enforces replace permissions using ($assetToReplace ?: $sourceAsset). When both IDs are provided, this expression resolves to the target asset so no permission check is performed against the source asset volume. When both assets are present, Craft copies the source file into the target and then deletes the source asset. There is no deletion check for for the source asset. An authenticated user who can replace files in one volume can delete assets in another volume where they do not have delete permission, as long as they can obtain a sourceAssetId, leading to broken content references and data loss. This issue has been fixed in versions 4.17.14 and 5.9.21.
Description: To issue and renew TLS certificates on behalf of customers, Cloudflare's Universal SSL feature automatically manages the CAA RRset for the customer's zone. This auto-managed RRset is permissive by design (e.g. 'issue "letsencrypt.org"' without parameters). On Universal SSL zones, Cloudflare's authoritative DNS serves this auto-managed RRset at query time, superseding any customer-configured CAA records on the zone. When a customer publishes a stricter CAA record using the RFC 8657 accounturi or validationmethods parameters, the Certificate Authority does not observe those parameters when evaluating the served RRset under RFC 8659. As a result, the RFC 8657 account-binding and validation-method-binding protections are not enforced end-to-end on Universal SSL zones. Successful exploitation could result in issuance of a browser-trusted TLS certificate to an attacker, enabling MITM against the affected domain. Exploitation is non-trivial in practice: an attacker would need to hold an ACME account at one of the Certificate Authorities in the served CAA RRset and to simultaneously satisfy domain control validation across the multiple geographically distinct Network Perspectives the CA relies on for Multi-Perspective Issuance Corroboration. Cloudflare prefixes are anycast-announced from hundreds of locations globally, raising the bar against single-vantage-point BGP hijacks. Any resulting misissuance of a browser-trusted certificate is subject to Certificate Transparency logging required by major browsers, and would be visible to CT monitoring. Mitigation: Customers requiring strict RFC 8657 enforcement need to disable Universal SSL on the affected zone. Universal SSL's automatic CAA management and customer-set RFC 8657 accounturi and validationmethods enforcement are mutually exclusive by the nature of the issue, so there is no in-product workaround that preserves both. Certificate Transparency monitoring is recommended for all customers as a general detection control. Credits: David Osipov (ORCID: https://orcid.org/0009-0005-2713-9242), independent researcher
Out of bounds read and write in Tint in Google Chrome prior to 150.0.7871.46 allowed a remote attacker to potentially perform out of bounds memory access via a crafted HTML page. (Chromium security severity: High)
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.